Details for Patent: 9,173,859

Title:	Uses of DPP IV inhibitors
Abstract:	The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
Inventor(s):	Dugi; Klaus (Dresden, DE), Himmelsbach; Frank (Mittelbiberach, DE), Mark; Michael (Biberach an der Riss, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Filing Date:	Jan 22, 2014
Application Number:	14/161,007
Claims:	1. A method of treating type 2 diabetes comprising administering to a patient in need thereof (a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine, or a therapeutically active salt thereof, in an oral dosage of 2.5 mg or 5 mg, and (b) metformin wherein the dose of metformin is 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a day), or 300 mg to 1000 mg once or twice a day, or as delayed-release metformin in a dose of 500 mg to 1000 mg once or twice a day, or 500 mg to 2000 mg once a day, or wherein the dose of metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total daily dose of metformin of 500-2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg metformin in delayed release form, or wherein the dose of metformin is 500 mg to 1000 mg. 2. The method according to claim 1, wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine and metformin are administered orally in the form of a fixed combination. 3. The method according to claim 2, wherein the fixed combination is a tablet or capsule. 4. The method according to claim 2, wherein the fixed combination is a tablet. 5. The method according to claim 2, wherein the dosage of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine is 2.5 mg. 6. The method according to claim 2, wherein the dosage of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine is 5 mg. 7. The method according to claim 2, wherein metformin is provided in a dose of 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a day), or 300 mg to 1000 mg once or twice a day, or as delayed-release metformin in a dose of 500 mg to 1000 mg once or twice a day, or 500 mg to 2000 mg once a day. 8. The method according to claim 1, wherein the dose of metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total daily dose of metformin of 500 mg to 2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg metformin in delayed release form. 9. The method according to claim 2, wherein the amount of metformin is 500 mg to 1000 mg. 10. The method according to claim 2, wherein the amount of metformin is 500 mg. 11. The method according to claim 2, wherein the amount of metformin is 850 mg. 12. The method according to claim 2, wherein the amount of metformin is 1000 mg. 13. A method of treating type 2 diabetes comprising administering twice daily to a patient in need thereof 1-[(4-methyl-quinazolin-2-yl)methyl]-3 -methyl-7-(2-butyn-1-y1)-8-(3-(R)-amino-piperidin-1 -yl)- xanthine in an oral dosage of 2.5 mg in fixed combination with metformin in an amount of 500 mg to 1000 mg. 14. An oral tablet formulation comprising 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine in an amount of 2.5 mg or 5 mg optionally in combination with metformin, and a pharmaceutically acceptable carrier or diluent. 15. The oral tablet according to claim 14, containing 500 mg to 1000 mg metformin. 16. A method of treating type 2 diabetes comprising administering to a patient in need thereof (a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine in a daily oral amount of 5 mg and (b) metformin, in the form of a fixed combination, wherein metformin is administered in a dose of 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a day), or 300 mg to 1000 mg once or twice a day, or as delayed-release metformin in a dose of 500 mg to 1000 mg once or twice a day, or 500 mg to 2000 mg once a day. 17. A method of treating type 2 diabetes comprising administering to a patient in need thereof (a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine in a daily oral amount of 5 mg and (b) metformin, in the form of a fixed combination, wherein the dose of metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total daily dose of metformin of 500-2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg metformin in delayed release form. 18. A method of treating type 2 diabetes comprising administering to a patient in need thereof (a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine in a daily oral amount of 5 mg and (b) metformin, in the form of a fixed combination, wherein the amount of metformin is 500 mg to 1000 mg. 19. The method according to claim 1, wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine is administered in a daily oral amount of 5 mg. 20. A method of treating type 2 diabetes comprising administering to a patient in need thereof the oral tablet of claim 14, wherein the daily oral amount of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine administered to said patient is 5 mg. 21. The method according to claim 5, wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3 -methyl-7-(2-butyn-1-y1)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dosage of 2.5 mg is administered twice daily. 22. The method according to claim 6, wherein 1[(4-methyl-quinazolin-2 -yl)methyl]-3-methyl-7-(2-butyn-1-y1)-8-(3-(R)-amino-piperidin-1-yl)-xant- hine in a dosage of 5mg is administered once daily.